Complete Wegovy vs Mounjaro Dosing Analysis for Private Patients
Private Prescription Advantages for Wegovy vs Mounjaro Dosing Decisions
The NHS weight management pathway typically requires a 6-month specialist referral process before considering Wegovy vs Mounjaro dosing options. Private prescription eliminates this bottleneck, providing immediate access to both semaglutide and tirzepatide treatments through qualified prescribers. Your clinical assessment directly addresses dosing suitability, contraindications, and individualised titration schedules without lengthy waiting periods.
EverydayMeds connects patients with GPhC-registered prescribers (#9012878) who specialise in weight management pharmacotherapy. This streamlined approach means you can begin either Wegovy's structured 16-week dose escalation or Mounjaro's dual-hormone protocol within days rather than months. Both treatments require careful dose monitoring and adjustment based on tolerability and response, making expert prescriber access crucial for optimal outcomes.
Wegovy vs Mounjaro Dosing Schedules: Complete Price Breakdown
Wegovy dosing follows a mandatory 5-step escalation: 0.25mg (£79.99, weeks 1-4), 0.5mg (£94.99, weeks 5-8), 1mg (£99.99, weeks 9-12), 1.7mg (£139.99, weeks 13-16), and 2.4mg maintenance (£209.99, week 17+). Our Intro Trio bundle (0.25mg, 0.5mg, 1mg) covers the first 12 weeks for £299.99, whilst the Getting Started bundles provide consecutive dose pairs from £169.99.
Mounjaro utilises a different tirzepatide dosing protocol, starting at 2.5mg weekly with escalations to 5mg, 7.5mg, 10mg, and maximum 15mg based on individual response. New customers apply code FIRST40 at checkout, whilst returning patients use DOSE25. Both medications require prescription-only access and cannot be purchased without clinical assessment and prescriber approval through our platform.
Clinical Evidence: Wegovy vs Mounjaro Dosing Efficacy
In clinical trials, patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks in the STEP 1 trial (Wilding et al., NEJM, 2021). The maintenance 2.4mg dose demonstrated sustained efficacy across multiple study populations. Wegovy's GLP-1 receptor agonism provides appetite suppression through hypothalamic appetite centres.
Mounjaro clinical trials showed tirzepatide's dual GIP/GLP-1 receptor agonism may produce different weight loss patterns compared to semaglutide monotherapy. However, direct head-to-head comparisons between Wegovy vs Mounjaro dosing protocols cannot be made due to different trial designs and patient populations. Both treatments require individualised dose optimisation based on tolerability and clinical response.
How Wegovy Works: GLP-1 Receptor Mechanism
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics the action of naturally occurring incretin hormones. Following injection, semaglutide binds to GLP-1 receptors in the brain's appetite control centres, particularly the hypothalamus and brainstem. This binding triggers satiety signals that reduce hunger sensations and promote feelings of fullness after smaller meal portions. The medication also slows gastric emptying, extending the duration of post-meal satiation. Wegovy's once-weekly dosing schedule maintains consistent receptor activation, supporting sustained appetite regulation throughout treatment.
Private Prescription Ordering Process for Wegovy vs Mounjaro
Begin with our 3-minute clinical assessment covering medical history, current medications, and weight management goals specific to your dosing preferences. Our prescribers review applications within 3 working days (24-hour express option available) to determine suitability for either Wegovy or Mounjaro protocols. Once approved, your chosen medication ships via next-day cold-chain delivery maintaining the required 2-8°C temperature throughout transport. The FlexTouch pen system requires no reconstitution or preparation, arriving ready for immediate use. Follow-up consultations ensure appropriate dose escalation timing and side effect monitoring throughout your treatment journey.
Storage and Practical Considerations: Wegovy vs Mounjaro Dosing
Wegovy pens must be stored in the refrigerator at 2-8°C before first use, offering a significant advantage with 6 weeks of room temperature stability once removed from cold storage. This extended stability period exceeds Mounjaro's 21-day room temperature limit, providing greater flexibility for travel and daily use. Each FlexTouch pen contains 4 doses of your prescribed strength, delivered through pre-loaded injection mechanisms. Dose escalation cannot be skipped or accelerated beyond the licensed schedule, as rapid titration increases gastrointestinal side effect risk. Proper injection technique and site rotation prevent lipodystrophy and ensure consistent medication absorption.
Switching Between Wegovy and Mounjaro: Dosing Considerations
Patients considering switches between Wegovy vs Mounjaro dosing protocols require careful prescriber supervision due to different receptor mechanisms and potency profiles. Cross-titration strategies account for previous semaglutide or tirzepatide exposure, current dose level, and reason for switching. Some patients may need washout periods between treatments, whilst others can transition directly under medical guidance.
EverydayMeds prescribers maintain comprehensive treatment records enabling informed switching decisions based on individual response patterns. Private prescription access allows flexible treatment adjustments without NHS formulary restrictions or specialist referral delays. Both medications remain available ensuring continuity of care regardless of initial treatment choice or subsequent modifications.
Expert Prescriber Support: Wegovy vs Mounjaro Dosing Optimisation
Our qualified prescribers provide ongoing support throughout your Wegovy vs Mounjaro dosing journey, monitoring treatment response and adjusting protocols based on individual needs. Regular check-ins ensure appropriate dose escalation timing, side effect management, and lifestyle modification integration alongside pharmaceutical intervention. This personalised approach optimises treatment outcomes whilst maintaining safety standards required for prescription-only medicines. Access our expert clinical team through EverydayMeds with new customer code FIRST40 or returning customer code DOSE25 applied at checkout: https://everydaymeds.co.uk/collections/wegovy.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
